01 / 01

REGEnLIFE

REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease

REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease Within treated patient group, trends showed improved cognitive and executive functions, improved language comprehension and verbal memory, in comparison to placebo group REGEnLIFE’s technology shown to be safe and well-tolerated by patients Initial...

Mar , 17

REGEnLIFE obtains the ISO 13485 certificate for its medical activity

Montpellier, December 3, 2019 An internationally recognized certification, ISO 13485: 2016, has been issued to REGEnLIFE which is developing an innovative technology for the Alzheimer’s disease by targeting the brain-gut axis. REGEnLIFE, an innovative startup specializing in neurotechnology, announces that it has obtained its certificate of conformity to the ISO...

Jan , 9
Thinking beyond the brain: The photomedical device of REGEnLIFE could monitor gut microbiota dysbiosis during Alzheimer’s disease to protect from memory loss

Thinking beyond the brain: The photomedical device of REGEnLIFE could monitor gut microbiota dysbiosis during Alzheimer’s disease to protect from memory loss

Barcelona, Spain. October 27, 2018. The REGEnLIFE company participated on October, 27thto the Clinical Trials in Alzheimer’s Disease (CTAD) conference in Barcelona, Spain. Clinical trial teams worldwide discussed new results for the development of the next generation of treatments for Alzheimer’s Disease in order to identify new candidate therapeutic strategies....

Oct , 27
REGEnLIFE presenting at ‘AAT-AD/PD’ Congress in Torino

REGEnLIFE presenting at ‘AAT-AD/PD’ Congress in Torino

REGEnLIFE participated at ‘Advances in Alzheimer’s and Parkinson’s Therapies’  Congress in Torino, Italy, and presented a poster of ‘Neuroprotective effect of a new photo-biomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support : a novel hypothesis for therapeutic approach of Alzheimer’s disease’ study....

Mar , 15
THINKING OUTSIDE THE BOX

THINKING OUTSIDE THE BOX

REGEnLIFE presentation selected for the highlights of the ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) international conference Read PDF...

Nov , 4